Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR5A | P47898 | 2/20 | 0.43 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.42 |
| ▸ | GHSR | Q92847 | 6/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | LTA4H | P09960 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20534762 | 0.85 | HTR5A (0.37) | HTR5ASLC2A1GHSRLTA4H | |
| SCHEMBL20534944 | 0.82 | GHSR (0.38) | HTR5ASLC2A1GHSRPOLBLTA4H | |
| SCHEMBL20534942 | 0.81 | GHSR (0.36) | HTR5AGHSRLTA4H | |
| SCHEMBL21216250 | 0.78 | POLB (0.54) | GHSRKDM4EHSD17B10POLBLTA4H | |
| SCHEMBL20536532 | 0.74 | LTA4H (0.35) | HTR5ASLC2A1GHSRPOLBLTA4H | |
| SCHEMBL20535067 | 0.72 | KDM4E (0.37) | KDM4EHSD17B10 | |
| SCHEMBL12694261 | 0.69 | HTT (0.46) | KDM4EHSD17B10POLB | |
| SCHEMBL21216115 | 0.68 | SIGMAR1 (0.42) | KDM4EHSD17B10 | |
| SCHEMBL20535084 | 0.67 | KDM1A (0.39) | — | |
| SCHEMBL24335832 | 0.66 | FDPS (0.40) | HTR5ASLC2A1GHSRSLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11161869-B2 | Thermally-cleavable protecting and linker groups | EVONETIX LTD. (GB) | 2021-11-02 | — | — | US | disclosed |
| US-20210107934-A1 | THERMALLY-CLEAVABLE PROTECTING AND LINKER GROUPS | SILICON VALLEY BANK | 2021-04-15 | — | — | US | disclosed |
| EP-3609866-A1 | THERMALLY-CLEAVABLE PROTECTING AND LINKER GROUPS | Evonetix Ltd (GB) | 2020-02-19 | — | — | EP | disclosed |
| WO-2018189546-A1 | THERMALLY-CLEAVABLE PROTECTING AND LINKER GROUPS | EVONETIX LTD (GB) | 2018-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210107934-A1 | THERMALLY-CLEAVABLE PROTECTING AND LINKER GROUPS | CTDSP1, RNGTT, SSU72 | HTR5A 2305/4885SLC2A1 1814/4885GHSR 4380/4885 |
| US-11161869-B2 | Thermally-cleavable protecting and linker groups | CTDSP1, RNGTT, SSU72 | HTR5A 2305/4885SLC2A1 1814/4885GHSR 4380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.